An FDA-approved GHRH analog used for GH deficiency diagnosis and treatment, with a favorable safety profile.
Molecular Weight
3357.9 Da
Half-Life
10–20 minutes
Typical Dose
200–500 mcg
Cycle Length
3–6 months
Description
Sermorelin (GHRH 1-29 NH2) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It was FDA-approved for the diagnosis of GH deficiency in children and is widely used off-label for adult GH optimization. Sermorelin is the shortest fully active fragment of GHRH, retaining the complete biological activity of the 44-amino acid native hormone. Its relatively short half-life (10–20 minutes) results in more physiological GH pulsatility compared to exogenous recombinant HGH, which produces supraphysiological and non-pulsatile GH levels. By working through the pituitary's natural regulatory mechanisms (including somatostatin feedback), sermorelin cannot produce the excessive GH levels associated with exogenous HGH, making it a safer approach to GH optimization. It is often combined with Ipamorelin for synergistic GH release.
Key Characteristics
Molecular FormulaC149H246N44O42S
Molecular Weight3357.9 Da
Half-Life10–20 minutes
Administration RoutesSubcutaneous injection
Typical Dose200–500 mcg
FrequencyDaily (bedtime)
Investigated Benefits
Increased GH secretion
Improved body composition
Enhanced sleep quality
Increased energy levels
Physiological GH pulsatility
* Benefits based on preclinical/animal research unless otherwise noted.
Peptide Protocol Education Portal
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.